Table II.
Percentage of lung tumors from smokers and non-smokers with gene alterations
| Tobacco smokea |
Unexposedb |
|||
|---|---|---|---|---|
| % tumors with mutations | % tumors with LOH | % tumors with mutations | % tumors with LOH | |
| Cell cycle | ||||
| CDKN2A | 4 (6/136) | 33 (8/24) | 0 (0/47) | 29 (5/17) |
| CDKN2B | NA | NA | NA | NA |
| RB1 | NA | 47 (47/99) | NA | 19 (10/53) |
| TP53 | 39c (627/1591) | 38 (47/125) | 26 (105/410) | 40 (14/35) |
| Cell signaling: Wnt | ||||
| APC | NA | 43 (31/72) | NA | 67 (4/6) |
| Cell signaling: MAPK/ERK | ||||
| BRAF | NA | NA | NA | NA |
| HRAS | 0 (0/122) | NA | 0 (0/42) | NA |
| KRAS | 20c (616/3114) | NA | 3 (22/696) | NA |
| NRAS | 0 (0/193) | NA | 0 (0/69) | NA |
| Cell signaling: apoptosis | ||||
| DCC | NA | 16 (13/81) | NA | 0 (0/9) |
| FHIT | NA | 57c (262/460) | NA | 27 (34/126) |
ERK, extracellular signal-regulated kinase.
a
Tumors from current or previous tobacco smokers.
b
Tumors from non-smokers (never smokers).
c
Per cent tumors with alteration statistically higher in smokers compared with unexposed, non-smokers (P < 0.01).